MARS 2 Trial: The Future of Pleurectomy Decortication in Pleural Mesothelioma

ByHolly Zink
MARS 2 Trial: The Future of Pleurectomy Decortication in Pleural Mesothelioma

Malignant pleural mesothelioma, a deadly cancer, often comes from asbestos exposure. It is hard to treat due to its aggressiveness and the challenges of full surgical removal.

The MARS 2 trial investigated if extended pleurectomy decortication (P/D) could boost survival and life quality in patients with resectable mesothelioma.

A new article looks into the MARS 2 trial’s results, explains clinical trials, and suggests why mesothelioma patients should join them.

Understanding Clinical Trials

Clinical trials are research studies conducted to evaluate new medical treatments, drugs, or procedures in humans. These trials are essential for advancing medical knowledge and improving patient care. Clinical trials are typically divided into several phases:

  • Phase I: Tests the safety and dosage of a new treatment in a small group of people.
  • Phase II: Evaluates the treatment’s efficacy and further assesses its safety in a larger group.
  • Phase III: Confirms the treatment’s effectiveness, monitors side effects, and compares it with standard or equivalent treatments in a large population.
  • Phase IV: Conducted after a treatment has been approved for public use to gather additional information on its long-term effects.

Clinical trials follow a rigorous protocol to ensure the reliability of the results and the safety of the participants. Randomized controlled trials (RCTs), like the MARS 2 trial, randomly assign participants to different treatment groups to minimize bias and provide the most robust evidence.

The MARS 2 Trial Findings

The MARS 2 trial compared two treatments for pleural mesothelioma. It pitted surgery plus chemo against chemo alone. Surprisingly, the chemo-alone group lived longer (24.8 months vs. 19.3 months). Also, the surgery group reported a lower quality of life, more side effects, and higher costs.

These findings challenge earlier beliefs about surgery for this cancer. Before, decisions were based on past cases, not controlled trials. The trial highlights the need for expert surgery and careful patient selection to ensure surgery’s benefits.

Why Patients Should Get Involved in Clinical Trials

Participation in clinical trials offers several benefits to patients:

  1. Access to Cutting-Edge Treatments: Clinical trials provide access to new and potentially more effective treatments that are not yet widely available.
  2. Contribution to Medical Research: By participating in clinical trials, patients contribute to the advancement of medical knowledge and help improve treatments for future patients.
  3. Close Monitoring: Clinical trial participants often receive more frequent and thorough medical monitoring, which can lead to better overall care.
  4. Potential for Better Outcomes: Some patients may experience better outcomes through access to innovative therapies and personalized treatment approaches.

Implications for Mesothelioma Patients

The MARS 2 trial highlights how complex treating pleural mesothelioma is and the importance of clinical trials. It shows that, in some cases, chemotherapy alone might improve survival more than surgery. However, it also stresses the need for careful patient selection and expert surgeons.

For pleural mesothelioma patients, joining trials like MARS 2 is key. It offers insights into their disease and treatments. They also get access to advanced therapies and help enhance mesothelioma treatment. Future trials will refine the roles of surgery, chemotherapy, and new treatments, making outcomes better for patients.

Hope for Improved Survival

The MARS 2 trial sheds light on treating pleural mesothelioma. It shows how clinical trials advance medical knowledge and care. Patients with mesothelioma can benefit by joining these trials. They get new treatments, better care, and help develop improved therapies.

As research progresses, clinical trials will continue to be vital. They offer hope for better survival and quality of life for patients.

Source:

Grosso, Federica, Luigi Cerbone, and Alessandra Curioni-Fontecedro. “MARS 2 Trial: The Future of Pleurectomy Decortication in Pleural Mesothelioma.” The Lancet. Respiratory Medicine, May 10, 2024, S2213-2600(24)00146-2. https://doi.org/10.1016/S2213-2600(24)00146-2.

Similar Posts

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Radiotherapy for Mesothelioma: Better But Still Limited
| |

Radiotherapy for Mesothelioma: Better But Still Limited

ByAlex Strauss

A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

A Second-Line Option for Mesothelioma?
| |

A Second-Line Option for Mesothelioma?

ByAlex Strauss

Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

Repeat HIPEC Improves Mesothelioma Survival
| |

Repeat HIPEC Improves Mesothelioma Survival

ByAlex Strauss

If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

Value of Mesothelioma Surgery Challenged for Healthy Patients
| |

Value of Mesothelioma Surgery Challenged for Healthy Patients

ByAlex Strauss

New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…